BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

被引：0
|
作者：
Ektare, V [1 ]
Liu, R. [2 ]
Stephens, J. [2 ]
Al Taie, A. [3 ]
Shelbaya, A. [3 ,4 ]
机构：
[1] Pharmerit India Private Ltd, Mumbai, Maharashtra, India
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [21] A HEALTH TECHNOLOGY ASSESSMENT OF A PROPOSED BIOSIMILAR FOR THE TREATMENT OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A UNITED STATES PAYER PERSPECTIVE
    Vaidya, N.
    Cosler, L.
    VALUE IN HEALTH, 2014, 17 (03) : A88 - A88
  • [22] THE BUDGET IMPACT OF SITAGLIPTIN VERSUS ORAL SEMAGLUTIDE FROM A US PAYER PERSPECTIVE
    Alsumali, A.
    Lautsch, D.
    Kowal, S.
    Li, Q.
    Campbell, C.
    Rajpathak, S.
    Wehler, E.
    VALUE IN HEALTH, 2020, 23 : S116 - S116
  • [23] ECONOMIC BURDEN OF ATOPIC DERMATITIS FROM A UNITED STATES PAYER PERSPECTIVE
    Joish, V. N.
    Sullivan, S. D.
    Hartisch, C.
    Kamalakar, R.
    Eichenfield, L. F.
    VALUE IN HEALTH, 2012, 15 (07) : A521 - A521
  • [24] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY FROM THE PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, R.
    Yeh, Y. C.
    Yang, K.
    Gao, X.
    Balk, M.
    Tang, B.
    VALUE IN HEALTH, 2020, 23 : S434 - S434
  • [25] BUDGET-IMPACT ANALYSIS (BIA) OF CHRONIC PAIN SYNDROMES FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL
    Reis Neto, J. P.
    Busch, J. M.
    VALUE IN HEALTH, 2018, 21 : S444 - S444
  • [26] Improving the Usefulness of Budget Impact Analyses: A US Payer Perspective
    Watkins, John B.
    Danielson, Dan
    VALUE IN HEALTH, 2014, 17 (01) : 3 - 4
  • [27] BUDGET IMPACT ANALYSIS OF BALLOON DILATION AND FUNCTIONAL ENDOSCOPIC SURGERY - A US PAYER PERSPECTIVE
    Holy, C.
    Ellison, J.
    Schneider, C.
    VALUE IN HEALTH, 2013, 16 (03) : A232 - A232
  • [28] BUDGET IMPACT MODEL FOR SELEXIPAG: TAKING A US PAYER PERSPECTIVE
    Beaudet, A.
    Tsang, Y.
    Hunsche, E.
    Drake, W.
    Bilir, S. P.
    VALUE IN HEALTH, 2016, 19 (03) : A243 - A244
  • [29] BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES
    Rencz, F.
    Gulacsi, L.
    Baji, P.
    Pentek, M.
    Brodszky, V.
    HAEMATOLOGICA, 2017, 102 : 295 - 296
  • [30] THE USE OF A DABIGATRAN-SPECIFIC REVERSAL AGENT: BUDGET IMPACT ANALYSIS FROM THE HOSPITAL PERSPECTIVE AND THE FRENCH PUBLIC PAYER PERSPECTIVE
    Jamet, N.
    Bourguignon, S.
    Le Lay, K.
    VALUE IN HEALTH, 2016, 19 (07) : A606 - A606
12345